Duchenne muscular dystrophy: initial results of Genethon's gene therapy trial
The initial results of Genethon's gene therapy trial for Duchenne muscular dystrophy were presented on Tuesday 23 April at the Myology 2024 congress in Paris.
AFM-Telethon
Welcome to AFM-Telethon's website
Latest news
Telethon 2023: 92,905,533 euros, an exceptional result. Thank you for your support!
92,905,533 is the final amount raised by the Telethon held on 8 and 9 December 2023. This exceptional result bears witness to the unfailing mobilization of millions of donors, volunteers, and partners throughout France and abroad.
I-Stem, coordinator of an innovative research consortium
Finding treatments for neuromuscular diseases by combining artificial intelligence, stem cells and pharmacological screening is the aim of the new DREAMS research consortium, coordinated by I-Stem. An unprecedented project!
Myotubular muscular dystrophy: trial results show efficacy on respiratory and motor function, but challenges remain
A gene therapy developed at Genethon by Ana Buj Bello's team is proving effective in a rare and very severe muscle disease: myotubular myopathy. Review of the results published online in The Lancet Neurology on November 15.
Most requested content
Our fight to cure
Access to this content has been blocked to respect your choice of consent.
To access this content, you must modify your preferences and accept at least one of the following services:
ou
Change my preferences60 years of fight against diseases
The French Muscular Dystrophy Association (AFM-Téléthon) is composed of patients and their families who are affected by genetic, rare and progressive diseases. Discover 60 years of fight.
Join the Telethon for french people abroad
You live abroad and want to be part of the great Telethon adventure? Join us!